Centre Hospitalier de Versailles
Le Chesnay, 78150, France
NCT Number: NCT07211854
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications.
Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Le Chesnay, 78150, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.
Other names: Antiplatelet therapy
Time frame: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations).
Time frame: Discharge from hospital (day 1)
The nature of antithrombotic treatments
Time frame: The follow-up period between 2013 and 2023
The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)
Time frame: The follow-up period between 2013 and 2025
The occurrence of haemorrhagic events of any kind
Franck Assayag
Other
Acronym: ASCADA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.